Tag:

Astellas

Latest Headlines

Latest Headlines

Former Creighton professor named chief medical officer at 23andMe

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Astellas enlists a wide-eyed animated bladder for Myrbetriq ad campaign

We're accustomed to animated characters in our drug advertising. But a perky... bladder?

Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq

We're accustomed to animated characters in our drug advertising. That cheerful, buzzing Nasonex bee. The gently fluttering Lunesta moth. The droopy, sad little blob that so needs Zoloft. But a perky... bladder?

Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use

Astellas and Medivation today said they are asking the FDA for approval for Xtandi to be used on patients with metastatic castration-resistant prostate cancer who have not received chemotherapy.

Astellas finally bails on Aveo, giving up on the thrice-failed tivozanib

Japan's Astellas Pharma has seen enough of tivozanib, washing its hands of the once-promising cancer drug and putting an end to a three-year collaboration with Aveo Oncology.

Aveo's cancer drug circles the drain after a scuttled Phase II trial

Aveo Oncology and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced.

On second thought, NICE backs limits on Xtandi use

The U.K.'s National Institute for Health and Care Excellence is known to change its mind. But this time, Britain's cost watchdog has set limitations on its recommendation for prostate cancer pill Xtandi--and maker Astellas is none too happy.

Astellas and Takeda continue to advance vaccine strategies

Astellas presented summary results from Phase III trials of the Protein Sciences' flu shot it plans to commercialize in Japan. Separately, Takeda signed a deal to begin selling a freeze-dried live attenuated chickenpox vaccine in Japan.

UPDATED: Astellas inks deal to create a portfolio of vaccine-focused biotechs

The partnership sees Astellas team up with ClearPath, a Maryland-based company that helps develop early-stage drugs.

Astellas' prostate-cancer prodigy Xtandi shines as pre-chemo treatment

Soon after Xtandi hit the market last year, analysts were figuring that the prostate cancer drug would help pump up that market to $9.1 billion by 2021.  And now, the drug has shown success in a Phase III trial eyeing Xtandi as a prechemo treatment for advanced prostate cancer.